Cancer-free survival of psoriasis patients treated with methotrexate and cyclosporine combination.
BACKGROUND
Combination of methotrexate and cyclosporine was used and reported to be effective for recalcitrant psoriasis patients. Also each agent is accused for development of malignancies.


OBJECTIVE
To evaluate the cancer-free survival of psoriasis patients who received methotrexate and cyclosporine treatment at the same time.


METHODS
Psoriasis patients who had been treated with combination of cyclosporine and methotrexate between March 2000 and April 2005 were questioned in 2011. A diagnosis of new cancer during follow-up period was asked and also each patient was evaluated by a questionnaire.


RESULTS
Seventeen psoriasis patients were not treated due to a diagnosis of new cancer during the follow-up period. Also none of them complained of possible symptoms of skin or lymphoproliferative malignancies. The median follow-up time was 76 months.


CONCLUSIONS
Psoriasis patients who had been treated with methotrexate and cyclosporine combination did not report a detected malignant disease.
Department of Dermatology, Ondokuz Mayis University , Samsun , Turkey.
Fatma
F
Aydin
Esra Pancar
EP
Yuksel
Nilgun
N
Senturk
Tayyar
T
Canturk
Ahmet Yasar
AY
Turanli
D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology*; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology; D011795:Surveys and Questionnaires; D014421:Turkey / Q000453:epidemiology
D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D008727:Methotrexate
Cyclosporine; malignancy; methotrexate; psoriasis